-

The Importance of Science-Based Decision-Making Highlighted in Latest Issue of Philip Morris International’s Scientific Update

- Science-based decision-making requires that researchers recognize and address their biases, use validated scientific methods, and publish their work transparently.

- As the market for heated tobacco products expands, the availability of accurate and non-misleading information about these products is vital.

LAUSANNE, Switzerland--(BUSINESS WIRE)--Philip Morris International Inc. (PMI) (NYSE: PM) has published the 10th issue of its Scientific Update, a regularly issued report on the company’s efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes.

PMI’s latest Scientific Update focuses on scientific evidence and the importance of relying on science to make decisions in a world too often clouded by personal and professional biases. It is guest-edited by Dr. Moira Gilchrist, Vice President Strategic & Scientific Communications at PMI.

“Humans can be terrible decision-makers, especially in the heat of the moment and when tensions are high,” Dr. Gilchrist explains. “Scientists in this field—whether working directly for tobacco companies or receiving funding from other sources—have a responsibility to take all necessary precautions to ensure our work is unbiased and accurate. This latest Scientific Update explains the research methodology PMI employs, which is aligned with that used by the pharmaceutical industry, and encourages all others working in this field to adhere to equally high standards.”

This issue also explores the latest research on smoke-free products published by PMI and independent analysts. It includes a review of 13 population health impact models, produced by PMI scientists in collaboration with leaders in tobacco harm reduction research. These models estimate how the health of a population could be affected by the presence or absence of smoke-free products in the market. The study—published in the peer-reviewed medical journal Nicotine & Tobacco Research—summarizes the strengths and weaknesses of the two approaches and demonstrates how future models can benefit from the inclusion of well-designed epidemiological study data. These findings will help to inform authorities as they consider various approaches to tobacco harm reduction.

Dr. Gizelle Baker, Director Global Scientific Engagement at PMI, answers common questions about heated tobacco products, explaining what they are and how they differ from cigarettes and e-vapor products and addressing common misconceptions about them. She describes several independent studies on unintended use recently reviewed on PMIScience.com, noting, “Generally, the data show that the population most likely to use electrically heated tobacco systems, are current smokers, with low uptake by youth and nonsmokers and a slightly higher but still low likelihood of uptake by former smokers.”

The recent decision by U.S. Food & Drug Administration (FDA) to authorize the marketing of PMI’s IQOS Tobacco Heating System as a Modified Risk Tobacco Product with reduced exposure information was a function of the U.S. law and also an example of a science-based approach to harm reduction. In the next issue, this topic will be explored in more detail.

The Scientific Update can be found at www.pmiscience.com/whats-new/scientific-update-10.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com.

Contacts

Jana Olson
Philip Morris International
T. +41 (0)58 242 4500
E. Jana.Olson@pmi.com

Philip Morris International


Release Versions

Contacts

Jana Olson
Philip Morris International
T. +41 (0)58 242 4500
E. Jana.Olson@pmi.com

More News From Philip Morris International

Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product

STAMFORD, CT--(BUSINESS WIRE)--Experts from Philip Morris International (PMI) (NYSE: PM) yesterday presented scientific evidence to the U.S. Food and Drug Administration’s (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) as part of the FDA’s process for a Modified Risk Tobacco Product (MRTP) designation for their ZYN nicotine pouch products. This designation would allow PMI’s U.S. family of businesses to communicate to U.S. legal-aged, 21+ adult cigarette smokers that switching comp...

Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

STAMFORD, CT--(BUSINESS WIRE)--Philip Morris International Inc. (NYSE: PM) today released a new white paper, “Human Cognition: The Next Frontier?”, inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the “superskill” of the futu...

PMI is Invested in America: Already Over $20 Billion of U.S.-Related Investments with Significant Further Amounts Planned

STAMFORD, CT--(BUSINESS WIRE)--Philip Morris International (NYSE: PM) and its U.S. businesses (PMI U.S.) are strongly committed to investing in America, with over $20 billion of PMI investments since 2022 majority-related to both acquiring and further investing in U.S. manufacturing capabilities, commercial rights and infrastructure, and U.S. jobs. With around $19 billion of these investments in 2022, including the acquisition of Swedish Match which generates the large majority of its revenues...
Back to Newsroom